|Isentress in Addition to OBT
Dec 15, 2007
Dr. Young, I have been reading with great interest that there are trials currently enrolling in which Isentress is being added to an already Optimized HAART therapy where the VL < 50. Is this sort of trial typical for a new drug or is Isentress thought to be capable of doing significant damage to the latent hiv reservoir when added to an OBT?
| Response from Dr. Young
Thank you for your post.
Raltegravir (Isentress), the first of the HIV integrase inhibitors prevents the establishment of latently infected cells by preventing integration of the HIV genome into the human chromosome.
This mechanism has generated a lot of interest in the notion that it's use might have additional benefit to persons who's circulating virus is suppressed. Such concepts remain highly experimental and have not (yet) been shown to be (1) true and (2) of any benefit.
It should be a very interesting set of studies to watch for. BY
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.